Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00277290
Status:
TERMINATED
Last Update Posted:
2010-02-22
First Post:
2006-01-12
Brief Title:
Study of XL999 in Patients With Previously Treated Ovarian Cancer
Sponsor:
Symphony Evolution Inc
Organization:
Symphony Evolution Inc
Study Overview
Official Title:
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Recurrent Ovarian Cancer
Status:
TERMINATED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to cardiac toxicities in the subjects
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial is being conducted at multiple sites to evaluate the activity safety and tolerability of XL999 when given weekly to patients with ovarian cancer that has previously been treated with platinum-based chemotherapy XL999 is a small molecule inhibitor of multiple kinases including VEGFR PDGFR FGFR FLT-3 and Src which are involved in tumor cell growth formation of new blood vessels angiogenesis and metastasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None